Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.30 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.30 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19682225 | 0.79 | IGF2R (0.47) | IGF2RALDH1A1LGALS8LGALS3LGALS4 | |
| SCHEMBL19682226 | 0.79 | IGF2R (0.47) | IGF2RALDH1A1LGALS8LGALS3LGALS4 | |
| SCHEMBL24251933 | 0.75 | IGF2R (0.48) | IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL16621011 | 0.64 | IGF2R (0.64) | IGF2RALDH1A1LGALS8LGALS3LGALS4 | |
| SCHEMBL22360309 | 0.64 | IGF2R (0.64) | IGF2RALDH1A1LGALS8LGALS3LGALS4 | |
| SCHEMBL24107719 | 0.64 | IGF2R (0.64) | IGF2RALDH1A1LGALS8LGALS3LGALS4 | |
| SCHEMBL16621008 | 0.64 | IGF2R (0.64) | IGF2RALDH1A1LGALS8LGALS3LGALS4 | |
| SCHEMBL10961423 | 0.62 | IGF2R (0.59) | IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL10961421 | 0.62 | IGF2R (0.59) | IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL21321251 | 0.61 | IGF2R (0.67) | IGF2RALDH1A1LGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190247495-A1 | NOVEL SYNTHETIC ANTICANCER, ANTIFUNGAL, AND ANTIBACTERIAL VACCINES | WAYNE STATE UNIVERSITY | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247495-A1 | NOVEL SYNTHETIC ANTICANCER, ANTIFUNGAL, AND ANTIBACTERIAL VACCINES | ERG28, DDOST, STT3A | IGF2R 249/4885KDM4E 4184/4885ALDH1A1 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.